1-(4-bromophenyl)-6-methoxyisoquinoline | 579815-94-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-(4-bromophenyl)-6-methoxyisoquinoline
• CAS: 579815-94-4
• 化学式: C₁₆H₁₂BrNO
• 分子量: 314.181
• InChiKey: WUNUUABPQLVYSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-bromophenyl)-6-methoxyisoquinoline 在 氢溴酸 、 溶剂黄146 作用下， 反应 5.0h， 生成 1-(4-bromophenyl)isoquinolin-6-ol
  参考文献：
  名称：

  Synthesis and Structure−Activity Studies of Novel Orally Active Non-Terpenoic 2,3-Oxidosqualene Cyclase Inhibitors

  摘要：

  New orally active non-terpenoic inhibitors of human 2,3-oxidosqualene cyclase (hOSC) are reported. The starting point for the optimization process was a set of compounds derived from a fungicide project, which in addition to showing high affinity for OSC from Candida albicans showed also high affinity for human OSC. Common structural elements of these inhibitors are an amine residue and an electrophilic carbonyl C atom embedded in a benzophenone system, which are at a distance of about 10.7 Angstrom. Considering that the keto moiety is in a potentially labile position, modifications of the substitution pattern at the benzophenone as well as annelated heteroaryl systems were explored. Our approach combined testing of the compounds first for increased binding affinity and for increased stability in vitro. Most promising compounds were then evaluated for their efficacy in lowering plasma total cholesterol (TC) and plasma low-density lipoprotein cholesterol (LDL-C) in hyperlipidemic hamsters. In this respect, the most promising compounds are the benzophenone derivative 1.fumarate and the benzo[d]-isothiazol 24.fumarate, which lowered TC by 40% and 33%, respectively.

  DOI：

  10.1021/jm021120f
• 作为产物：
  描述：

  4-bromo-N-[2-(3-methoxy-phenyl)-ethyl]-benzamide 在 sodium sulfate 、 三氯氧磷 作用下， 以 甲苯 、 乙腈 为溶剂， 反应 28.0h， 生成 1-(4-bromophenyl)-6-methoxyisoquinoline
  参考文献：
  名称：

  Synthesis and Structure−Activity Studies of Novel Orally Active Non-Terpenoic 2,3-Oxidosqualene Cyclase Inhibitors

  摘要：

  New orally active non-terpenoic inhibitors of human 2,3-oxidosqualene cyclase (hOSC) are reported. The starting point for the optimization process was a set of compounds derived from a fungicide project, which in addition to showing high affinity for OSC from Candida albicans showed also high affinity for human OSC. Common structural elements of these inhibitors are an amine residue and an electrophilic carbonyl C atom embedded in a benzophenone system, which are at a distance of about 10.7 Angstrom. Considering that the keto moiety is in a potentially labile position, modifications of the substitution pattern at the benzophenone as well as annelated heteroaryl systems were explored. Our approach combined testing of the compounds first for increased binding affinity and for increased stability in vitro. Most promising compounds were then evaluated for their efficacy in lowering plasma total cholesterol (TC) and plasma low-density lipoprotein cholesterol (LDL-C) in hyperlipidemic hamsters. In this respect, the most promising compounds are the benzophenone derivative 1.fumarate and the benzo[d]-isothiazol 24.fumarate, which lowered TC by 40% and 33%, respectively.

  DOI：

  10.1021/jm021120f

文献信息

• Aminoalkyl-substituted benzo-heterocyclic compounds
  申请人：Hoffmann-La Roche Inc.

  公开号：US05856503A1

  公开（公告）日：1999-01-05

  Aminoalkyl-substituted benzo-heterocyclic compounds of the formula ##STR1## wherein M, Q, R and T are as defined in the specification, as well as acid addition salts thereof. These compounds are useful as cholesterol level lowering agents and as antimycotic agents.

  公式为 ##STR1## 的氨基烷基取代苯并杂环化合物，其中M、Q、R和T如规范中所定义，以及其酸加成盐。这些化合物可用作降低胆固醇水平的剂和抗真菌剂。
• Aminoalkyl-substituierte benzo-heterocyclische Verbindungen
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0778271A2

  公开（公告）日：1997-06-11

  Aminoalkyl-substituierte benzo-heterocyclische Verbindungen der Formel worin Rentweder eine Gruppe der Formel TH, Alkyl, Halogen, N(R2,R21), CONH2, CN, NO2, CF3, OH oder Alkyl (O oder S), R2 und R21Alkyl oder H und QCycloalkyl, gegebenenfalls substituiertes Phenyl oder gegebenenfalls durch OH substituiertes Alkyl Alkenyl oder ist, oder worin eins von R und T Halogen oder H und das andere H, Alkyl, Halogen, N(R2,R21), CONH2, CN, NO2, CF3, OH oder Alkyl (O oder S) und Qeine Gruppe der Formel A1Alkyl oder Alkenyl und A2Cycloalkyl, Cycloalkyl-alkyl oder gegebenenfalls substituiertes Alkyl oder Alkenyl oder A1 zusammen mit A2 gegebenenfalls substituiertes Alkylen oder Alkenylen, L1eine direkt oder über O, NH oder N(Alkyl oder Alkanoyl) an die Benzogruppe gebundene Gruppe L, L2eine über O, NH oder N(Alkyl oder Alkanoyl) an die Phenylgruppe gebundene Gruppe L, LAlkylen Alkenylen oder Cycloalkylen-alkylen, die von M ausgehende gestrichelte Bindung fakultativ ist, Meine 2- oder 3-gliedrige Gruppierung, die ein O- oder S-Atom oder eine Gruppe S(O), S(O)2 oder C(O) und/oder bis zu zwei N-Atome oder Gruppen N(R6) und/oder bis zu zwei Gruppen C(R6) oder CH(R6) enthalten kann, jedoch insgesamt zumindest ein gegebenenfalls substituiertes Heteroatom enthält und R6H oder Alkyl ist, und Säureadditionssalze davon.

  式中的氨基烷基取代的苯并异环化合物 其中 任一式中的一个基团 TH、烷基、卤素、N(R2,R21)、CONH2、CN、NO2、CF3、OH 或烷基（O 或 S）、 R2 和 R21 为烷基或 H，以及 Q是环烷基、任选取代的苯基或任选被 OH 取代的烷基、烯基或烃基。 或其中 R 和 T 的一个是卤素或 H，另一个是 H、烷基、卤素、N(R2,R21)、CONH2、CN、NO2、CF3、OH 或烷基（O 或 S），以及 Q 是式中的基团 A1 是烷基或烯基，以及 A2 是环烷基、环烷基-烷基或任选取代的烷基或烯基，或 A1 与 A2 一起为任选取代的亚烷基或烯基、 L1 是直接或通过 O、NH 或 N（烷基或烷酰基）与苯偶氮基键合的基团 L、 L2 是通过 O、NH 或 N（烷基或烷酰基）与苯基键合的基团 L、 LA是烯烃基或环烷烃基、 从 M 开始的虚线键是可选的、 我的 2 元或 3 元基团，可包含一个 O 原子或 S 原子或一个基团 S（O）、S（O）2 或 C（O）和/或最多两个 N 原子或基团 N（R6）和/或最多两个基团 C（R6）或 CH（R6），但总共至少包含一个任选取代的杂原子，并且是 是 R6H 或烷基、 及其酸加成盐。
• US5856503A
  申请人：——

  公开号：US5856503A

  公开（公告）日：1999-01-05
• Synthesis and Structure−Activity Studies of Novel Orally Active Non-Terpenoic 2,3-Oxidosqualene Cyclase Inhibitors
  作者：Henrietta Dehmlow、Johannes D. Aebi、Synèse Jolidon、Yu-Hua Ji、Elisabeth M. von der Mark、Jacques Himber、Olivier H. Morand

  DOI：10.1021/jm021120f

  日期：2003.7.1

  New orally active non-terpenoic inhibitors of human 2,3-oxidosqualene cyclase (hOSC) are reported. The starting point for the optimization process was a set of compounds derived from a fungicide project, which in addition to showing high affinity for OSC from Candida albicans showed also high affinity for human OSC. Common structural elements of these inhibitors are an amine residue and an electrophilic carbonyl C atom embedded in a benzophenone system, which are at a distance of about 10.7 Angstrom. Considering that the keto moiety is in a potentially labile position, modifications of the substitution pattern at the benzophenone as well as annelated heteroaryl systems were explored. Our approach combined testing of the compounds first for increased binding affinity and for increased stability in vitro. Most promising compounds were then evaluated for their efficacy in lowering plasma total cholesterol (TC) and plasma low-density lipoprotein cholesterol (LDL-C) in hyperlipidemic hamsters. In this respect, the most promising compounds are the benzophenone derivative 1.fumarate and the benzo[d]-isothiazol 24.fumarate, which lowered TC by 40% and 33%, respectively.